ArticlePloS one2014
Development of a mimotope vaccine targeting the Staphylococcus aureus quorum sensing pathway.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Current Strategies for Combating Biofilm-Forming Pathogens in Clinical Healthcare-Associated Infections.Indian journal of microbiology · 2024Review
- Critical Assessment of the Prospects of Quorum-Quenching Therapy forInternational journal of molecular sciences · 2023Review
- Epitope-Based Vaccines against theVaccines · 2022Article
- Recent Strategies to Combat Biofilms Using Antimicrobial Agents and Therapeutic Approaches.Pathogens (Basel, Switzerland) · 2022Review
- Engineering an Antibody V Gene-Selective Vaccine.Frontiers in immunology · 2021Article
- Quorum Sensing as Antivirulence Target in Cystic Fibrosis Pathogens.International journal of molecular sciences · 2019Review
- SAROTUP: a suite of tools for finding potential target-unrelated peptides from phage display data.International journal of biological sciences · 2019Article
- Recent Advances in Anti-virulence Therapeutic Strategies With a Focus on Dismantling Bacterial Membrane Microdomains, Toxin Neutralization, Quorum-Sensing Interference and Biofilm Inhibition.Frontiers in cellular and infection microbiology · 2019Review
- Computational B-cell epitope identification and production of neutralizing murine antibodies against Atroxlysin-I.Scientific reports · 2018Article
- VLP-based vaccine induces immune control of Staphylococcus aureus virulence regulation.Scientific reports · 2017Article
- Pathogen-specific deep sequence-coupled biopanning: A method for surveying human antibody responses.PloS one · 2017Article
- Identification of Anti-CA125 Antibody Responses in Ovarian Cancer Patients by a Novel Deep Sequence-Coupled Biopanning Platform.Cancer immunology research · 2016Article
- Interfering with Bacterial Quorum Sensing.Perspectives in medicinal chemistry · 2016Article
- Investigational therapies targeting quorum-sensing for the treatment of Staphylococcus aureus infections.Expert opinion on investigational drugs · 2015Review
- Affinity selection of epitope-based vaccines using a bacteriophage virus-like particle platform.Current opinion in virology · 2015Review
- Correction: Development of a Mimotope Vaccine Targeting the Staphylococcus aureus Quorum Sensing Pathway.PloS one · 2015Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
A major hurdle in vaccine development is the difficulty in identifying relevant target epitopes and then presenting them to the immune system in a context that mimics their native conformation. We have engineered novel virus-like-particle (VLP) technology that is able to display complex libraries of random peptide sequences on a surface-exposed loop in the coat protein without disruption of protein folding or VLP assembly. This technology allows us to use the same VLP particle for both affinity selection and immunization, integrating the power of epitope discovery and epitope mimicry of traditional phage display with the high immunogenicity of VLPs. Previously, we showed that using affinity selection with our VLP platform identifies linear epitopes of monoclonal antibodies and subsequent immunization generates the proper antibody response. To test if our technology could identify immunologic mimotopes, we used affinity selection on a monoclonal antibody (AP4-24H11) that recognizes the Staphylococcus aureus autoinducing peptide 4 (AIP4). AIP4 is a secreted eight amino acid, cyclized peptide produced from the S. aureus accessory gene regulator (agrIV) quorum-sensing operon. The agr system coordinates density dependent changes in gene expression, leading to the upregulation of a host of virulence factors, and passive transfer of AP4-24H11 protects against S. aureus agrIV-dependent pathogenicity. In this report, we identified a set of peptides displayed on VLPs that bound with high specificity to AP4-24H11. Importantly, similar to passive transfer with AP4-24H11, immunization with a subset of these VLPs protected against pathogenicity in a mouse model of S. aureus dermonecrosis. These data are proof of principle that by performing affinity selection on neutralizing antibodies, our VLP technology can identify peptide mimics of non-linear epitopes and that these mimotope based VLP vaccines provide protection against pathogens in relevant animal models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.